2024 AHA/ACC等多学会肥厚型心肌病管理指南
该指南由AHA/ACC联合多学会制定,基于2022年9月至2023年5月的文献检索,更新了2020版肥厚型心肌病指南的推荐,为临床医生管理肥厚型心肌病患者提供指导。
要点
- 肥厚型心肌病仍是全球常见的遗传性心脏病。
- 指南基于新证据对2020版推荐进行了更新。
- 推荐旨在指导临床医生管理肥厚型心肌病患者。
核心结论
- 2024版指南更新了2020版肥厚型心肌病指南的推荐,以新证据指导临床管理。
临床怎么用
- 临床医生可依据该指南更新对肥厚型心肌病患者的管理推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy. METHODS: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate. STRUCTURE: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy" have been updated with new evidence to guide clinicians.
引用
- Ommen, Ho, Asif, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024. PMID: 38727647. doi:10.1016/j.jacc.2024.02.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。